Knockdown of KLK11 Reverses Oxaliplatin Resistance by Inhibiting Proliferation and Activating Apoptosis Via Suppressing the PI3K/AKT Signal Pathway in Colorectal Cancer Cell

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Mar 3

PMID 29497313

Citations 23

Authors

Yiyi Zhang

Zongbin Xu

Yanwu Sun

Pan Chi

Xingrong Lu

Affiliations

Soon will be listed here.

Abstract

Introduction: Kallikrein 11 (KLK11) plays a crucial role in drug-resistance to oxaliplatin (L-OHP) in the treatment of metastatic colorectal cancer (mCRC). The study aimed to investigate the role of KLK11 in chemoresistance, and to clarify the mechanism underlying reverse of L-OHP resistance by knockdown of KLK11.

Materials And Methods: Resistance to oxaliplatin was induced in HCT-8 (HCT-8/L-OHP) colorectal adenocarcinoma cell lines by exposing cells to increasing concentrations of L-OHP. MTT, RT-qPCR, and Western blot were used to evaluate the resistance to L-OHP. We then knocked down KLK11 in HCT-8/L-OHP cells to explore the mechanism through which KLK11 reverses L-OHP resistance. The mRNA and protein expression of KLK11 in tissues from mCRC patients were detected by RT-qPCR and immunohistochemistry.

Results: The drug resistance index (RI) of HCT-8/L-OHP cell line to L-OHP, 5-Fluorouracil (5-FU), Irinotecan (CPT-11), Vincristine (VCR) and Cis-diamminedichloroplatinum (CDDP) were 10, 5.35, 3.23, 1.28, and 6.64, respectively. Increased expression of multi-drug resistant genes , , and were detected in HCT-8/L-OHP cell line. Moreover, the activated PI3K/AKT pathway was related to L-OHP-resistance. Knockdown of in HCT-8/L-OHP cell reversed L-OHP-resistance by inhibiting cell growth and activating apoptosis via suppressing the PI3K/AKT signaling pathway. Moreover, high expression of KLK11 in chemoresistant-patients was associated with lymph node metastases and histopathology.

Conclusion: KLK11 was highly expressed in chemoresistant-patients and L-OHP-resistant cell lines. Moreover, L-OHP resistance was associated with activated PI3K/AKT signal pathway. Knockdown of can reverse L-OHP resistance by blocking PI3K/AKT signaling pathway.

Citing Articles

Zhang Y, Hou H, Zhang X, Lan H, Huo X, Duan X Dig Dis Sci. 2024; 70(1):262-284.

PMID: 39604668 DOI: 10.1007/s10620-024-08715-z.

Zinc Oxide Nanoparticles and Cancer Chemotherapy: Helpful Tools for Enhancing Chemo-sensitivity and Reducing Side Effects?.

Vaghari-Tabari M, Jafari-Gharabaghlou D, Mohammadi M, Hashemzadeh M Biol Trace Elem Res. 2023; 202(5):1878-1900.

PMID: 37639166 DOI: 10.1007/s12011-023-03803-z.

In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer.

Lee C, Lee A, Wei P, Liu Y, Chang Y, Huang C Sci Rep. 2023; 13(1):4366.

PMID: 36927770 PMC: 10020571. DOI: 10.1038/s41598-023-31331-2.

Novel strategies to reverse chemoresistance in colorectal cancer.

Ma S, Zhang J, Yan T, Miao M, Cao Y, Cao Y Cancer Med. 2023; 12(10):11073-11096.

PMID: 36645225 PMC: 10242875. DOI: 10.1002/cam4.5594.

Computational Tactics for Precision Cancer Network Biology.

Park H, Miyano S Int J Mol Sci. 2022; 23(22).

PMID: 36430875 PMC: 9695754. DOI: 10.3390/ijms232214398.

References

Li B, Li J, Xu W, Guan X, Qin Y, Zhang L . Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget. 2014; 5(22):11576-87. PMC: 4294385. DOI: 10.18632/oncotarget.2596. View

Edwards B, Noone A, Mariotto A, Simard E, Boscoe F, Henley S . Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2013; 120(9):1290-314. PMC: 3999205. DOI: 10.1002/cncr.28509. View

Xiang Z, Kang Q, Xiang X . Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line. Genet Mol Res. 2015; 14(3):11013-22. DOI: 10.4238/2015.September.21.14. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Pandurangan A . Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev. 2013; 14(4):2201-5. DOI: 10.7314/apjcp.2013.14.4.2201. View

Debela M, Beaufort N, Magdolen V, Schechter N, Craik C, Schmitt M . Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem. 2008; 389(6):623-32. DOI: 10.1515/BC.2008.075. View

Gillet J, Gottesman M . Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2009; 596:47-76. DOI: 10.1007/978-1-60761-416-6_4. View

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

Benedix F, Kuester D, Meyer F, Lippert H . [Influence of mucinous and signet-ring cell differentiation on epidemiological, histological, molecular biological features, and outcome in patients with colorectal carcinoma]. Zentralbl Chir. 2012; 138(4):427-33. DOI: 10.1055/s-0031-1283870. View

10.

Hennessy B, Smith D, Ram P, Lu Y, Mills G . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. DOI: 10.1038/nrd1902. View

11.

Ando K, Oki E, Saeki H, Kasagi Y, Tsuda Y, Zaitsu Y . Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. Anticancer Res. 2015; 35(11):6207-11. View

12.

Liu X, Quan B, Tian Z, Xi H, Jia G, Wang H . Elevated expression of KLK8 predicts poor prognosis in colorectal cancer. Biomed Pharmacother. 2017; 88:595-602. DOI: 10.1016/j.biopha.2017.01.112. View

13.

Paliouras M, Diamandis E . Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol. 2008; 29(2):63-75. DOI: 10.1159/000135686. View

14.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

15.

Qiu J, Liu P, Shi C, Han B . Low-grade myofibroblastic sarcomas of the maxilla. Oncol Lett. 2015; 9(2):619-625. PMC: 4301534. DOI: 10.3892/ol.2014.2790. View

16.

Sawayama H, Hayashi N, Honda S, Baba Y, Toyama E, Watanabe M . Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to.... Int J Clin Oncol. 2010; 15(1):70-6. DOI: 10.1007/s10147-009-0013-5. View

17.

Hawk N, Long T, Imam M, Mathew B, Kim S, Chen Z . Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. Am J Clin Oncol. 2014; 38(6):543-9. DOI: 10.1097/01.coc.0000437899.28701.03. View

18.

Paliouras M, Borgono C, Diamandis E . Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007; 249(1):61-79. DOI: 10.1016/j.canlet.2006.12.018. View

19.

Wen Y, Wang Q, Zhou C, Yan D, Qiu G, Yang C . Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol. 2011; 104(5):516-24. DOI: 10.1002/jso.21981. View

20.

Yuan W, Xiaoyun H, Haifeng Q, Jing L, Weixu H, Ruofan D . MicroRNA-218 enhances the radiosensitivity of human cervical cancer via promoting radiation induced apoptosis. Int J Med Sci. 2014; 11(7):691-6. PMC: 4025168. DOI: 10.7150/ijms.8880. View